尔康制药前三季营收超10亿元 海外项目与技术研发多点推进

Core Insights - The company reported a positive performance in Q3 2025, with a revenue of 1.006 billion yuan, representing a year-on-year growth of 17.81%, and a net profit of 39.5759 million yuan, showing a significant increase of 255.40% [1][3] - The company is expanding its overseas operations, with a $10 million investment in a comprehensive formulation production project in Tanzania, which is progressing as planned and is expected to meet GMP certification conditions by Q4 2025 [1][2] - The company is also investing $8 million in a new injection production project in Nigeria, which is part of its overall development strategy to enhance economic benefits and competitiveness [2] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.006 billion yuan, a 17.81% increase year-on-year [1] - The net profit for the same period was 39.5759 million yuan, reflecting a substantial growth of 255.40% compared to the previous year [1] Overseas Expansion - The company’s subsidiary in Tanzania is investing $10 million in a production project, with construction and equipment installation progressing on schedule [1] - The project aims to complete equipment debugging by Q4 2025 and is preparing for drug registration to facilitate market entry [1][2] - An additional investment of $8 million is planned for a new injection production project in Nigeria, expected to take 18 months to complete [2] Technological Development - The company’s subsidiary, Hangzhou Longde Intelligent Technology Co., Ltd., is focusing on AI applications in rehabilitation robots and security, and has obtained various medical device operating qualifications [2] - The subsidiary has also expanded its intellectual property portfolio, completing new software copyrights and patent applications to enhance its competitive edge [2] Market Outlook - Market analysts view the company’s stable growth in Q3 2025 as a result of solid progress in industrial breakthroughs and technology development, which supports its future stability [3] - The collaborative advancement across multiple business lines is seen as a strong foundation for the company’s ongoing development [3]